InvestorsHub Logo
Followers 16
Posts 1545
Boards Moderated 0
Alias Born 12/13/2009

Re: rayovacAAA post# 453990

Thursday, 03/14/2024 12:46:53 AM

Thursday, March 14, 2024 12:46:53 AM

Post# of 462568
The only surprise to me is that it has taken this long for the ambulance chasers to bring a class action lawsuit. There is so much we don't know about 2-73 when it comes to the statistical analysis plans, etc., that it's almost impossible to have absolute confidence in the data. What we do know is that regulatory authorities in Europe have given the go ahead for a filing that could lead to commercial approval. Once again, we don't know the degree of analysis that has been done by those European authorities. The FDA position on the data is a total unknown and it may not have seen any more data than has been publicly released. We are fifteen months past AVXL's announcement of a successful 2b/III AD trial. The data set is complete and has presumably been seen by quite a few people, including several new distinguished employees. After all this time, I find it almost impossible to believe all this has been some elaborate scam by Missling. As a consequence, I have continued to hold the majority of my original position in spite of the Rett EXCELLENCE trial failure. We'll know when we know.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News